



Oligodendrocyte precursor survival and differentiation requires chromatin remodeling by Chd7 and Chd8

Corentine Marie^a, Adrien Clavairoly^a, Magali Frah^a, Hatem Hmidan^a, Jun Yan^b, Chuntao Zhao^c, Juliette Van Steenwinckel^b, Romain Daveau^a, Bernard Zalc^a, Bassem Hassan^a, Jean-Léon Thomas^{a,d}, Pierre Gressens^b, Philippe Ravassard^a, Ivan Moszer^a, Donna M. Martin^e, Q. Richard Lu^c, and Carlos Parras^{a,1}

^aInstitut du Cerveau et de la Moelle Épinière, INSERM U1127, CNRS UMR 7225, GH Pitié-Salpêtrière, Sorbonne Université, 75013 Paris, France; ^bPromoting Research Oriented Towards Early CNS Therapy, INSERM, Université Paris Diderot, Sorbonne Paris Cité, F-75019 Paris, France; ^cDepartment of Pediatrics, Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; ^dDepartment of Neurology, Yale School of Medicine, New Haven, CT 06510; and ^eDepartment of Pediatrics and Human Genetics, University of Michigan Medical School, Ann Arbor, MI 48109

Edited by Michael E. Greenberg, Harvard Medical School, Boston, MA, and approved July 17, 2018 (received for review February 22, 2018)

Oligodendrocyte precursor cells (OPCs) constitute the main proliferative cells in the adult brain, and deregulation of OPC proliferation-differentiation balance results in either glioma formation or defective adaptive (re)myelination. OPC differentiation requires significant genetic reprogramming, implicating chromatin remodeling. Mounting evidence indicates that chromatin remodelers play important roles during normal development and their mutations are associated with neurodevelopmental defects, with CHD7 haploinsufficiency being the cause of CHARGE syndrome and CHD8 being one of the strongest autism spectrum disorder (ASD) high-risk-associated genes. Herein, we report on uncharacterized functions of the chromatin remodelers *Chd7* and *Chd8* in OPCs. Their OPC-chromatin binding profile, combined with transcriptome and chromatin accessibility analyses of *Chd7*-deleted OPCs, demonstrates that *Chd7* protects nonproliferative OPCs from apoptosis by chromatin closing and transcriptional repression of *p53*. Furthermore, *Chd7* controls OPC differentiation through chromatin opening and transcriptional activation of key regulators, including *Sox10*, *Nkx2.2*, and *Gpr17*. However, *Chd7* is dispensable for oligodendrocyte stage progression, consistent with *Chd8* compensatory function, as suggested by their common chromatin-binding profiles and genetic interaction. Finally, CHD7 and CHD8 bind in OPCs to a majority of ASD risk-associated genes, suggesting an implication of oligodendrocyte lineage cells in ASD neurological defects. Our results thus offer new avenues to understand and modulate the CHD7 and CHD8 functions in normal development and disease.

oligodendrocyte | chromatin remodeling | CHARGE | autism spectrum disorder | transcription regulation

Beyond the well-known function in saltatory conduction of action potentials, oligodendrocytes (OLs) have been shown to metabolically support axons with lactate shuttling through the myelin sheaths (1, 2). Accumulating evidence over the last years has demonstrated a role for neuronal activity-dependent adaptive myelination in adult brain plasticity, which confers a key neurological function to OL lineage cells (3). Oligodendrocyte precursor cells (OPCs) originate from focal regions of ventricular zones in the brain and spinal cord (4, 5) and, through proliferation and migration, occupy the whole CNS before starting to differentiate into myelinating OLs (6). Unlike most precursor cells, OPCs remain abundant in the adult CNS, being one of its neural cell subtypes (7, 8). OPCs need to keep a tight balance between proliferation, survival, and differentiation. This balance is crucial to maintain the OPC pool while contributing to myelin plasticity in adult life, and to remyelination in diseases, such as multiple sclerosis (MS). A large diversity of extrinsic signals (9), as well as many transcription factors [TFs, reviewed in Emery and Lu (10)], have been involved in OPC proliferation, survival, and differentiation. However, the mechanism for how these signals are integrated in the nucleus to balance OPC behavior is largely unknown.

OPC differentiation requires profound changes in chromatin and gene expression (10, 11). TFs, such as Sox10, Olig2, Nkx2.2, or Ascl1, are key regulators of OL differentiation by directly controlling transcription of genes implicated in this process (12–15) but being already expressed in OPCs, it is still unclear how these TFs control the induction of differentiation. A growing body of evidence suggests that some of these TFs work together with chromatin factors during transcriptional initiation/elongation to drive robust transcription (16). Accordingly, Olig2 and Brg1, a SWI/SNF chromatin remodeler expressed in oligodendroglia, have been found to cooperate and promote the expression of OPC differentiation genes (15).

Chd7 and Chd8, ATP-dependent nucleosome remodeling factors belonging to the subgroup III of the chromodomain helicase DNA-binding (CHD) family modulate the chromatin configuration to regulate the temporal and spatial expression of genes during development (17, 18) and, more specifically, neurogenesis (19–23). Importantly, while *CHD7* mutations are the

Significance

Oligodendrocyte precursor cells (OPCs) constitute the main proliferative cells in the adult brain and deregulation of OPC proliferation-differentiation balance results in either glioma formation or defective (re)myelination. Mutations in chromatin remodelers *CHD7* and *CHD8* are the cause of CHARGE syndrome and some autism spectrum disorders (ASD). Here we show that *Chd7* protects OPCs from apoptosis by chromatin closing and gene repression of *p53*, while *Chd7* induces chromatin opening and gene activation of OPC-differentiation regulators. *Chd7* is, however, dispensable for oligodendrocyte stage progression, consistent with *Chd8* compensatory function, as suggested by their common chromatin-binding profiles, including ASD-risk-associated genes. Our results thus involve oligodendroglia in ASD and CHARGE and offer new avenues to understand and modulate CHD7/CHD8 functions in normal and pathological brain development.

Author contributions: C.M. and C.P. designed research; C.M., A.C., M.F., H.H., J.Y., J.V.S., and C.P. performed research; C.Z., P.G., P.R., D.M.M., and Q.R.L. contributed new reagents/analytic tools; C.M., R.D., B.Z., I.M., and C.P. analyzed data; and C.M., B.H., J.-L.T., and C.P. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

This open access article is distributed under [Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 \(CC BY-NC-ND\)](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Data deposition: The data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, <https://www.ncbi.nlm.nih.gov/geo> (accession no. GSE116601).

¹To whom correspondence should be addressed. Email: carlos.parras@upmc.fr.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1802620115/-DCSupplemental.

Published online August 14, 2018.

main cause of CHARGE syndrome, an autosomal-dominant syndrome that often impairs normal brain development, leading to cognitive disabilities (24), *CHD8* is one of the nine high-confidence autism spectrum disorder (ASD)-risk genes (25, 26) and autism features are found in some CHARGE syndrome patients (27). We recently showed that *Chd7* expression is highly enriched in OL lineage cells and by *Chd7* loss-of-function (LOF) experiments demonstrated that *Chd7* is required for myelination and remyelination through cooperation with *Sox10* and activation of myelin-associated gene expression (28). In the present study, we have investigated the role of *Chd7* in OPC cell fates and explored the possible redundancy with its paralog gene, *Chd8*. Indeed, *Chd8* is another CHD subgroup III protein previously shown to interact with *Chd7* (21, 29), and although *Chd8* plays an important role in neurodevelopment (22, 23), its function in glial cells has not been investigated so far. Here, using a time-controlled *Chd7* deletion in OPCs, we show that *Chd7* inactivation leads to decreased OPC survival specifically in noncycling OPCs and that, in parallel, OPC differentiation is reduced without affecting OL stage progression due to *Chd8* functional compensation. Combining *Chd7/Chd8* chromatin-binding profiles from in vivo OPCs with transcriptome and chromatin accessibility analyses of *Chd7*-deleted OPCs, we demonstrate that mechanistically, *Chd7* promotes OPC survival via chromatin closing and transcriptional repression of *p53/Trp53*, while conversely, *Chd7* binding is required for chromatin opening and transcriptional activation of key regulators of OPC differentiation. Finally, integration of chromatin-binding profiles and associated epigenetic signals from OL lineage cells suggest that *Chd7/Chd8* remodelers and *Olig2/Sox10* TFs

cooperate to activate oligodendroglia stage-specific genes in a time-controlled manner.

Results

Chd7 Binds to Promoters and Enhancers of Genes Involved in OPC Differentiation, Proliferation, and Survival.

Chd7 is known to be required for the normal onset of myelination (28) but its involvement in early stages of oligodendroglial cell lineage has not been addressed. In support for *Chd7*'s role in OPC cell-fate decisions, we found that *Chd7* protein was expressed at the OPC stage (Fig. 1 A–C, arrowheads, and *SI Appendix, Fig. S1*) and accumulated in immature OLs (iOLs) (Fig. 1 A–C, arrows, and *SI Appendix, Fig. S1*) (28). OPCs show a tight balance between proliferation and differentiation by mechanisms that are not completely understood. We therefore investigated the possible regulation of *Chd7* in OPC proliferation, survival, and differentiation by generating a chromatin-binding profile of *Chd7* in purified OPCs. Using magnetic-assisted cell sorting (MACS) from mouse postnatal day (P) 7 cortices (Fig. 1D), we prepared highly purified O4⁺ oligodendroglia (98%, being ~80% of PDGFRα⁺ OPCs and ~20% of Nkx2.2⁺/CNP⁺ iOLs) (*SI Appendix, Fig. S2 A–C*), directly used to perform *Chd7* chromatin-binding analysis by ChIP combined with high-throughput sequencing (ChIP-seq) (Fig. 1D), and identified 11,655 *Chd7*-binding sites associated with 6,018 protein-coding genes (Fig. 1 E and F). Remarkably, almost all (94%) of *Chd7*-bound genes had a dynamic expression pattern in OL lineage cells (*SI Appendix, Fig. S2D*). To investigate whether *Chd7* binding in OPCs was stage-specific, we compared *Chd7*-binding sites in OPCs to our previous data from OLs (28). We found that *Chd7*




Fig. 1. *Chd7* binds to genes involved in OPCs proliferation, differentiation, and survival. (A and B) Immunostaining of *Chd7* with PDGFRα and CC1 (A) or Olig1 and CC1 (B) in the CC of P24 mice. Gray arrowheads show OPCs and gray arrows show OLs. (Scale bar, 10 μm.) (C) Scheme representing expression levels of different markers depending on OL stage. (D) Diagram representing MACS sorting of O4⁺ cells of P7 wild-type mice followed by *Chd7* ChIP-seq. (E and F) Venn diagrams depicting the overlap of *Chd7*-binding sites (E) and bound genes (F) in OPCs and OLs, with examples of genes involved in OPC differentiation (blue), cell death (orange), and cell cycle (red). (G) Barplot representing the GO analysis of the OPC- or OL-only *Chd7*-bound genes. (H) Representative ChIP-seq tracks for *Chd7* and control IgG together with active epigenetic marks (H3K27ac and H3K4me3) of *Trp53*, *Ccnd1*, and *Sox10* genes in OPCs and OLs. (I and J) Graph showing the number of correlations of *Chd7* peaks in OPCs (blue) and OLs (black) compared with the position in enhancer regions (I) and promoter regions (J).

binds only 10% of common sites at both stages (1,279) (Fig. 1E), corresponding to ~30% of commonly bound genes (2,168) (Fig. 1F). These genes included key regulators of oligodendrogenesis (*Ascl1*, *Olig1*, *Sox10*, *Nkx2.2*) (Fig. 1F and H). Notably, gene ontology (GO) enrichment analysis indicated that, in OPCs, Chd7 binds genes involved in proliferation (such as *Ccnd1*, *Cdk4*, and *Cdk6*) and apoptosis (such as *p53/Trp53*), while myelin-genes (such as *Mobp* and *Omg*) were Chd7-bound only in OLs (Fig. 1F–H). Therefore, Chd7 binds in a stage-specific manner to genes implicated in oligodendroglial cell survival, proliferation, and differentiation.

We assessed the cell-type specificity of Chd7 chromatin binding by comparing its binding profile in OPCs, embryonic stem cells (ESCs) (30), OLs (28), and neonatal cerebellar granule precursors (GNPs) (21). Interestingly, Chd7-binding profiles in ESCs, OPCs, and OLs overlapped only in 151 peaks (representing 1% of OPC peaks), with 14% of OPC peaks shared with ESCs (SI Appendix, Fig. S2E). Similarly, only 63 peaks overlapped between OPCs, OLs, and GNPs, with 4% of OPC peaks shared with GNPs (SI Appendix, Fig. S2F). The Chd7 chromatin binding is thus mostly cell-type- and lineage-stage-specific.

We next examined whether Chd7 preferentially binds enhancer elements in OPCs, as has been reported in ESCs (17, 30). To identify enhancer elements in OPCs, we took advantage of oligodendroglia-specific ChIP-seq datasets for Sox10 and Olig2, key TFs activating oligodendrogenesis (15, 28). In oligodendroglial cells, Sox10/Olig2-commonly bound regions (12,094) (SI Appendix, Fig. S2G) display strong H3K27ac marks (SI Appendix, Fig. S2I), characteristic of active regulatory elements (31), and are mainly located outside promoter regions (31) (SI Appendix, Fig. S2H) and thus correspond to active enhancers. We found that Chd7 binds many H3K27ac⁺ Sox10/Olig2-active enhancers both in OPCs and OLs (Fig. 1I). Unexpectedly, in OPCs Chd7 binding was especially enriched in promoter regions defined by either H3K4me3/H3K27ac active promoter marks or the Genomatix portal (Fig. 1J and SI Appendix, Fig. S2J and K), contrary to rare Chd7 binding to promoters in other cell types, such as OLs, GNPs (21), and ESCs (30). Taken together, our data suggest that Chd7 binding to promoters is temporally restricted to the OPC stage while Chd7 binds to enhancers both in OPCs and OLs.

Chd7 Regulates Genes Involved in OPC Proliferation, Differentiation, and Survival. To investigate whether the expression of Chd7-bound genes in OPCs was modified upon Chd7 LOF, we induced Chd7-conditional deletion (*Chd7iKO*) in neonatal OPCs, using *PDGFRa-CreER^T* and *Chd7^{Flox}* alleles (32, 33) (Fig. 2A). Neonatal tamoxifen administration allowed us to delete *Chd7* in ~90% of OPCs, as shown by Chd7 immunofluorescence and qRT-PCR at P7 (Fig. 2B and C and SI Appendix, Fig. S3A). We then purified O4⁺ cells from *Chd7iKO* (*PDGFRa-CreER^T; Chd7^{Flox/Flox}*) or control (*Chd7^{Flox/Flox}*) (Fig. 2A) P7 cortices. Because the proportion of OL stages (80% of OPCs and 20% iOLs) was not altered by the loss of *Chd7* (SI Appendix, Fig. S2C), we could collect comparable oligodendroglial cell populations from mutant and control brains.

The impact of *Chd7* LOF on gene transcription was assessed by genome-wide transcriptome analysis (RNA-seq) (Fig. 2A). Surprisingly, despite Chd7 being described mostly as an activator of transcription (17, 18, 21), many deregulated genes in *Chd7iKO* OPCs (3,096 genes, fold-change > 1.2 and *P* < 0.05) were up-regulated (67%, 2,070 genes) (Fig. 2D), while only 33% were down-regulated (1,026 genes) (Fig. 2D). GO analysis indicated that many up-regulated genes were associated with cell survival, apoptosis, and cell proliferation (Fig. 2E and SI Appendix, Fig. S3B–D). In contrast, genes associated with OL differentiation were exclusively found among down-regulated genes (Fig. 2F and SI Appendix, Fig. S3C and D). Almost all genes Chd7-bound and deregulated in *Chd7iKO* OPCs had a dynamic expression pattern during OPC differentiation (SI Appendix, Fig. S3E). On the one




Fig. 2. Chd7-regulated genes involved in OPCs proliferation, differentiation, and survival. (A) Diagram representing tamoxifen (Tam) administration to control (*Ctrl*) and *Chd7iKO* (*iKO*) mice at P1 and P4 followed by MACS-sorting of O4⁺ cells at P7. Cells are then used for either RNA-seq or ATAC-seq. (B) Immunostaining of P7 brain sections showing that all PDGFRα⁺ OPCs express Chd7 in the CC of *Ctrl* mice, while only a few OPCs maintain Chd7 expression in *iKO* mice. Star shows a Chd7-expressing OPC in *iKO*. (Scale bars, 10 μm.) (C) Quantification of Chd7⁺ OPCs as a percentage of total PDGFRα⁺ cells in the CC and cortex (Ctx) of P7 *Ctrl* and *iKO* mice. Data are presented as mean ± SEM (*n* = 5). Exact *P* values can be found in Dataset S2. ****P* < 0.001. (D) Pie chart showing the relative percentage and number of genes that were significantly up-regulated or down-regulated in P7 *iKO* O4⁺ cells compared with *Ctrl* (fold-change > 1.2; *P* < 0.05). (E) GO analysis of the up-regulated (red) and down-regulated (blue) genes in *Chd7iKO* cells compared with *Ctrl*. Numbers indicate the number of genes of each category. (F) Heatmap representing the expression of 100 most different genes in *Ctrl* and *iKO* O4⁺ cells (*n* = 7 *Ctrl* and 5 *iKO*). (G) Venn diagram depicting the overlap of Chd7-binding genes in OPCs with down-regulated (blue) or up-regulated (red) genes in *iKO* cells with examples of Chd7-bound genes involved in OL differentiation (blue), cell death (orange), and cell cycle (red).

hand, one-third (31%) of up-regulated genes were bound by Chd7, including cell-cycle regulators (e.g., *Ccnd1*, *Cdk4* and *Cdk6*) and regulators of cell survival/apoptosis (e.g., *p53/Trp53*, *Bax*, *Apaf1*) (Fig. 2G). On the other hand, a majority of down-regulated genes (59%) were bound by Chd7, including genes involved in OPC differentiation (such as *Sox10*, *Nkx2.2*, *Gpr17*, and *Sirt2*) (Fig. 2G). Therefore, Chd7 regulates OPC gene

transcription by both repressing apoptosis/proliferation genes and activating differentiation genes.

Chd7 and Chd8 Bind to the Same Regulatory Regions of OPC Differentiation, Proliferation, and Survival Genes. Combined Chd7 chromatin-binding and transcriptomics analysis of *Chd7* mutant OPCs indicate that, despite Chd7 binding to many genes involved in different OPC functions, only a fraction of these genes are deregulated upon *Chd7* deletion (Fig. 2G). We therefore asked if Chd8 cooperates with Chd7 and compensates for *Chd7* LOF in the regulation of Chd7-bound genes. We thus investigated Chd8 protein expression in the postnatal brain. Indeed, Chd7 and Chd8 proteins showed similar expression patterns in postnatal brain oligodendroglia; Chd8 protein was detected in PDGFR α ⁺ OPCs (Fig. 3A and C, arrowheads) and found at higher levels in differentiating OLs (CC1^{high} cells) (Fig. 3A and C, arrows), and its levels decreased in mature MOG⁺ OLs (Fig. 3B and C, arrows), in agreement to *Chd8* transcript pattern in postnatal brain cells shown by RNA-seq databases (34, 35). Furthermore, upon LPC-induced focal demyelination of the adult corpus callosum (CC), Chd8 was detected at high levels in PDGFR α ⁺ OPCs and

iOLs (CC1⁺/Olig1⁺ cells) in/around lesions during remyelination (SI Appendix, Fig. S4 A–E), similar to Chd7 expression (SI Appendix, Fig. S1 J and K). Chd8 protein may thus compensate for *Chd7* LOF in differentiating OPCs/iOLs.

To investigate whether Chd7 and Chd8 regulate common OPC genetic programs, a genome-wide Chd8 chromatin-binding profile was established from in vivo purified OPCs and then compared with Chd7-binding sites. Chd8 and Chd7 share many sites (6,418 regions) (Fig. 3D), representing 55% of Chd7-bound regions. A majority (57.6%) of Chd8-binding sites were found in promoter regions (Fig. 3E), consistent with reports of other cell types (22, 36). In addition, Chd8, like Chd7, also bound a large number of OPC active enhancers (Fig. 3F). Interestingly, the majority of Chd7-bound genes were also bound by Chd8 (86%, 5,184 genes), including genes associated with cell differentiation, proliferation, and survival (Fig. 3G). Furthermore, the genes encoding well-known regulators of oligodendroglial development (*Ascl1*, *Nkx2.2*, *Olig1*, *Olig2*, *Sox10*), oligodendroglial markers (*Pdgfra*, *Cspg4*, *Gpr17*, *Apc*, *Itrp2*, *Mbp*), R checkpoint regulators (*Ccnd1*, *Cdk4*, *Cdk6*), and apoptotic/survival genes (*p53*, *Bax*, *Apaf1*) were all bound by both Chd7 and Chd8 (Fig. 3G and I). Of




Fig. 3. Chd8 binds together with Chd7 to OPC differentiation, proliferation, and survival genes. (A) Chd8 immunolabeling of P14 brain sections showing Chd8 expression in all maturing OLs (CC1^{high}-expressing cells, arrows) of the CC, as well as in neurons of the cortex (Ctx). (A1) Detail of the *Inset* in A showing that, beside the high Chd8 expression in maturing OLs (white arrows) and neurons (gray arrows), a low level of Chd8 expression is detected in few OPCs (PDGFR α ⁺ cells, white arrowheads) but is hardly detectable in astrocytes (CC1^{low}-expressing cells, gray arrowheads). (Scale bar, 20 μ m.) (B) Immunofluorescence at P21 showing young mature MOG⁺ OLs still expressing Chd8 (white arrows). (B1) Detail of the *Inset* shown in B; gray arrows correspond to Chd8⁺ neurons. (Scale bar, 20 μ m.) (C) Summary representation of Chd8 and Chd7 expression at different stages of the OL cell lineage, as identified by PDGFR α , CC1, and MOG expression. (D) Venn diagrams depicting the overlap of Chd7-, Chd8-, and Brg1-binding sites in OPCs. (E and F) Graph showing the number of correlations of Chd7 (blue), Chd8 (red), and Chd7-Chd8 (green) peaks in OPCs compared with the position in promoter regions (E) or enhancer regions (F). (G) Overlap of Chd7- and Chd8-bound genes in OPCs with examples of genes involved in OL cell differentiation (blue), cell death (orange), and cell cycle (red). (H) Overlap between ASD-risk genes and Chd7- and Chd8-bound genes in OPCs. (I) Representative ChIP-seq tracks for Chd8 and control IgG together with Olig2, Sox10, Chd7, and active epigenetic marks (H3K27ac and H3K4me3) in *Olig2*, *Olig1*, *Sox10*, *Mog*, and *Cdk1* gene regions in OPCs.

note, *Chd7* and *Chd8* share very few binding sites with Brg1 (Fig. 3D), another chromatin remodeler that cooperates with Olig2 to control OL differentiation (15), suggesting that *Chd7/Chd8* and Brg1 may regulate distinct OPC differentiation processes. Given that we integrated ChIP-seq datasets obtained from rat and mouse, we asked whether binding is conserved between species. To address this question, we compared the *Chd8*-binding profile between our in vivo mouse-purified O4⁺ cells with rat OPC primary cultures (37) and observed a large overlap (87%) (SI Appendix, Fig. S5B) of bound genes between species, comparable to the reported overlap of *Chd8* ChIP-seq replicates from the same sample (36, 38). Furthermore, global alignment of *Chd7*-, *Chd8*-, Olig2-, and Sox10-binding peaks to active regulatory regions found in oligodendroglial cells, but not in other neural cells (Fig. 3I and SI Appendix, Figs. S5–S8), strongly support cell-type-specific binding conservation to regulatory elements in orthologous chromosomal regions, consistent with conservation in TF-to-TF connections and regulatory networks found in mammals by the ENCODE project (39). Taken together, our findings show that *Chd7* and *Chd8* chromatin remodelers, acting together or functionally compensating for each other, regulate the genetic networks controlling OPC proliferation, survival, and differentiation.

Finally, we assessed whether *Chd7* and *Chd8* binding to OPC genes was enriched among 201 ASD risk genes described previously (40, 41). A large number of them were *Chd7/Chd8*-bound genes in OPCs (90 of 201 and 136 of 201, respectively) (Fig. 3H and Dataset S1), but only *Chd7* was found to be significantly enriched over its genome-wide binding to protein-coding genes ($P < 0.0034$, hypergeometric test), suggesting that OPCs may contribute to brain developmental defects in ASD patients displaying mutations in either *CHD8*, *CHD7*, or their targets among ASD-risk genes.

***Chd7* LOF Reduces Brain OPC Pool Without Impacting OPC Proliferation.** To determine the consequences of *Chd7* LOF in OPC population, we quantified PDGFR α ⁺ OPCs in P7 brains and found that *Chd7iKO* brains display less numerous OPCs in

the CC and cortex, compared with controls (~30% and ~60%, respectively) (Fig. 4A and B). *Chd7* deletion thus affects either OPC proliferation or survival. To assess the possible impact of *Chd7* deletion on OPC proliferation, we examined proliferation-associated genes in our OPC RNA-seq datasets and found an up-regulation of key regulators of both cell-cycle checkpoints (*Ccnd1*, *Cdk6*, *Ccne1*, *Ccna1*, *Cdk2*, *Ccnb1*, *Cdk1*) and proliferation markers (*Mki67*, *Mcm2*) (Fig. 4C). Therefore, we assessed the proliferative status of *Chd7iKO* OPCs in P7 brains. Surprisingly, the number of MCM2⁺ or Ki67⁺ proliferating OPCs in the CC and cortex was similar between *Chd7iKO* and controls (Fig. 4D and E and SI Appendix, Fig. S9A–E). We then addressed possible changes in cell-cycle length measuring the proportion of OPCs in S-phase (labeled by short pulse of BrdU) among cycling OPCs (MCM2⁺/PDGFR α ⁺ cells) and found no changes in cell-cycle length between *Chd7iKO* and controls at P7 (SI Appendix, Fig. S9G and H).

These results led us to hypothesize that the up-regulation of cell-cycle genes may result from a selective reduction of non-proliferating OPCs. The number of cycling and noncycling OPCs was counted in *Chd7iKO* and control brains, showing a reduction of nonproliferating OPCs (Mcm2⁻/PDGFR α ⁺ cells) (Fig. 4D and E and SI Appendix, Fig. S9B), leading to an increased MCM2⁺ fraction of OPCs (Fig. 4F and SI Appendix, Fig. S9C) in *Chd7iKO* brains. Similar results were obtained upon *Chd7* deletion in OPCs at a later time point (SI Appendix, Fig. S9I and J). Therefore, *Chd7*-deficient brain OPCs are not impacted in their proliferation or cell-cycle length. In contrast, nonproliferating *Chd7*-deficient OPCs are reduced in numbers, suggesting that *Chd7* may regulate OPC survival.

***Chd7* Promotes OPC Survival by Chromatin-Closing and Transcription Repression of *p53*.** We next investigated whether OPCs underwent abnormal apoptosis in P7 *Chd7iKO* brains. Despite being actively removed by microglia (SI Appendix, Fig. S9K), apoptotic OPCs labeled with antiactivated Caspase3-recognizing antibodies (Casp3⁺/PDGFR α ⁺ cells) were observed in *Chd7iKO* brains, while they were rare in controls (Fig. 5A and B). Furthermore, the apoptosis GO category was highly enriched among the up-regulated transcripts of purified OPCs from *Chd7iKO* brains compared with controls (RNA-seq) (Figs. 2E and 5C). Notably, transformation-related protein 53 (Trp53 also named p53), a main regulator of apoptosis, and recently linked to *Chd7*-mediated defects in CHARGE syndrome (42), was among the up-regulated transcripts (Fig. 5C) and confirmed by qRT-PCR (SI Appendix, Fig. S10A). Several p53 target genes involved in apoptosis (e.g., *Bax*, *Apaf1*) were also up-regulated, but not those involved in cell-cycle arrest (expecting *p21*) or DNA repair (Fig. 5C). We therefore assessed for p53 protein up-regulation in P7 cerebral OPCs and found p53⁺ OPCs (15% of CC OPCs and 40% of cortical OPCs) in *Chd7iKO* brains but not in controls (Fig. 5D–F). Interestingly, 90% of *Chd7iKO* OPCs expressing p53 were postmitotic (Mcm2⁻/PDGFR α ⁺ cells) (Fig. 5G), confirming that loss of *Chd7* results in specific apoptosis of non-cycling OPCs likely mediated by p53 up-regulation (Fig. 5M).

To obtain more insight into *Chd7* regulation of *Chd7*-bound genes, we compared the chromatin accessibility of these genes between *Chd7iKO* and control OPCs. Therefore, we generated a genome-wide chromatin accessibility profiling by Tn5 transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) combined with sequencing (43), from purified O4⁺ cells from either *Chd7iKO* or control cortices (Fig. 2A). We obtained a high genome-wide correlation between transcript expression and chromatin accessibility in the transcription start sites, indicating efficient open chromatin mapping (SI Appendix, Fig. S10B). Interestingly, the promoter elements bound by *Chd7* and *Chd8* in the *p53/Trp53* locus showed larger chromatin accessibility in *Chd7iKO* OPCs compared with controls (Fig. 5H), suggesting that




Fig. 4. *Chd7* LOF in OPCs does not affect cell proliferation. (A) Immunolabeling of PDGFR α ⁺ cells in the CC and cortex (Ctx) of P7 *Control* (*Ctrl*) and *Chd7iKO* (*iKO*) mice. (Scale bars, 10 μ m.) (B) Quantification of PDGFR α ⁺ cells (nb/mm²) in the CC and Ctx of P7 *Ctrl* and *iKO* mice. Data are presented as mean \pm SEM ($n = 5$). (C) Barplot representing the log fold-change (LogFC) of genes involved in cell cycle and proliferation between *iKO* and *Ctrl* mice. Dashed gray line represent FC = 1.2 ($n = 7$). (D) Immunostaining of MCM2 and PDGFR α in the CC from P7 *Ctrl* and *iKO* mice. (Scale bars, 10 μ m.) (E) Quantification of the density of MCM2⁺ and MCM2⁻ PDGFR α ⁺ OPCs (nb/mm²) in the CC of P7 *Ctrl* and *iKO* mice. Data are presented as mean \pm SEM ($n = 3$). (F) Quantification of MCM2⁺ cells as a percentage of total PDGFR α ⁺ cells in the CC of P7 *Ctrl* and *iKO* mice. Data are presented as mean \pm SEM ($n = 3$). Exact P values can be found in Dataset S2. * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.




Fig. 5. Chd7 promotes OPC survival through p53 down-regulation. (A) Immunostaining of Casp3 and PDGFR α in the CC of P7 *iKO* mice. (Scale bar, 10 μ m.) (B) Quantification of Casp3⁺ OPCs as a percentage of OPCs in P7 *Ctrl* and *iKO* mice. Data are presented as mean \pm SEM ($n = 3$ *Ctrl* and 4 *iKO*). (C) Barplot representing the LogFC of *Trp53* and p53 target-genes involved in apoptosis pathway (red), cell-cycle arrest (orange), or DNA repair (yellow) between *iKO* and *Ctrl* mice. Dashed gray line represents FC = 1.2 ($n = 7$ *Ctrl* and 5 *iKO*). (D) Immunostaining of p53 and PDGFR α in the CC from P7 *Ctrl* and *iKO* mice. (Scale bars, 10 μ m.) (E and F) Quantification of p53⁺ OPCs (nb/mm², E) or as a percentage of OPCs (F) in the CC and Ctx of P7 *Ctrl* and *iKO* mice. Data are presented as mean \pm SEM ($n = 3$ *Ctrl* and 4 *iKO*). (G) Quantification of MCM2⁺ and MCM2⁻ cells as a percentage of total p53⁺ cells in the CC of *iKO* P7 mice. Data are presented as mean \pm SEM ($n = 3$ *Ctrl* and 4 *iKO*). (H) Representative tracks for *Trp53* locus integrating: (i) ChIP-seq data for Olig2 and Sox10, Chd7, and Chd8 in OPCs and; (ii) ATAC data from *Ctrl* and *iKO* P7 OPCs. (I, Left) Diagram representing tamoxifen (Tam) administration at P1 and P4 and PFT injection at P3, P4, and P5 followed by tissue collection at P7. (Right) Immunostaining of PDGFR α in the CC from P7 *Ctrl*, *iKO* and *iKO*+PFT mice. (Scale bars, 10 μ m.) (J) Quantification of p53⁺ cells as

Chd7 normally represses *p53/Trp53* transcription by binding and inducing chromatin closing at these regulatory elements.

To demonstrate that p53 up-regulation was responsible for *Chd7iKO* OPCs apoptosis, we used Pifithin- α (PFT) (Fig. 5I), a p53 inhibitor that impedes p53 activation (44). Interestingly, treatment with PFT reduced the number of p53⁺ OPCs (Fig. 5J) and rescued the normal density of OPCs in *Chd7iKO* CC (Fig. 5I and K), indicating that Chd7 promotes OPC survival by inhibiting p53-mediated apoptosis. Notably, rescuing noncycling OPCs permitted to recover a similar proportion of MCM2⁺ OPCs between control and *Chd7iKO* brains (Fig. 5L), confirming that *Chd7*-deletion does not have an impact on brain OPC proliferation. Together, these results indicate that Chd7 contributes to the survival of postmitotic OPCs by inhibiting *p53/Trp53* through chromatin closing at its promoter elements (Fig. 5M).

Chd7 Is Required to Induce OPC Differentiation but Not OL Stage Progression, by Chromatin-Opening, and Gene Activation of *Sox10*, *Nkx2.2*, and *Gpr17*. We then assessed for the Chd7 role in OPC differentiation that was not been specifically addressed in our previously study (28). In depth analysis of down-regulated transcripts in *Chd7iKO* oligodendroglia showed reduced expression of key regulators of OPC differentiation, such as *Sox10*, *Gpr17*, *Nkx2.2*, and *Tcf7l2* (Fig. 6A). *Chd7* LOF also impacted the expression of some regulators of OL maturation (*Sirt2*, *Myrf*, *Zfp488*) and in myelin protein genes (*Cnp*, *Omg*) (Fig. 6A). These results were confirmed by qPCR analysis (SI Appendix, Fig. S10A). Therefore, we quantified the different OL cell types in the CC of *Chd7iKO* mice at postnatal stage P7, a peak time for cortical OPC differentiation. P7 *Chd7iKO* mice showed a strong decrease (~40%) of Nkx2.2⁺ iOLs compared with control brains (Fig. 6B and C), indicating that *Chd7* deletion in OPCs impairs normal OPC differentiation. The OPC/iOL ratio was, however, not modified in *Chd7iKO* brains, due to a similar reduction in OPC and iOL populations (SI Appendix, Fig. S10C and D). The number of Nkx2.2⁺, *Itr2*⁺ (35), and APC⁺ (45) cells, which we show by immunofluorescence, mark successive stages of OL cell lineage according to their transcript expression pattern (SI Appendix, Fig. S10E–H), were similarly decreased (Fig. 6B and C), indicating that *Chd7* loss do not alter OL stage progression once OPC differentiation is started. In agreement with this interpretation, we found a similar CC1/Olig1 immunofluorescence, which distinguishes three different stages of OL differentiation (13), between *Chd7iKO* mice and controls (SI Appendix, Fig. S11). Taken together, these data indicate that *Chd7* deletion impairs OPC capacity to start differentiation but not the normal progression once differentiation has started (Fig. 6F).

To assess whether OPC apoptosis was sufficient to account for the reduction of differentiating OLs in *Chd7iKO* brains, or if Chd7 functions in survival and differentiation could be separated, we rescued OPC survival and numbers by PFT treatment (Fig. 5I and K). Remarkably, the number of iOLs (Nkx2.2⁺ cells) in the CC was the same in PFT-treated and untreated *Chd7iKO* mice (Fig. 6D and E). Therefore, the rescue of OPC survival is not sufficient to recover normal differentiation of *Chd7iKO*

a percentage of OPCs in the CC of P7 *Ctrl*, *iKO*, *Ctrl*+PFT, and *iKO*+PFT mice. Data are presented as mean \pm SEM ($n = 3$ *Ctrl*, 4 *iKO*, 3 *Ctrl*+PFT and 3 *iKO*+PFT). (K) Quantification of PDGFR α ⁺ cells (nb/mm²) in the CC of P7 *Ctrl*, *iKO*, *Ctrl*+PFT and *iKO*+PFT mice. Data are presented as mean \pm SEM ($n = 5$ *Ctrl*, 5 *iKO*, 3 *Ctrl*+PFT and 3 *iKO*+PFT). (L) Quantification of MCM2⁺ cells as a percentage of OPCs in the CC of P7 *Ctrl*+PFT and *iKO*+PFT mice. Data are presented as mean \pm SEM ($n = 3$). (M) Scheme representing Chd7 function in OPC survival. Proliferative OPCs (light blue), noncycling OPCs (blue) in *Ctrl*, *iKO*, and *iKO*+PFT mice. Exact P values can be found in Dataset S2. * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.




Fig. 6. Chd7 promotes the expression of genes involved in OPC differentiation and maturation. (A) Barplot of the LogFC of genes involved in OPC differentiation, OL maturation, or coding for myelin proteins between P7 *Chd7iKO* (*iKO*) and *Ctrl*. The dashed gray line represents fold-change = 1.2 ($n = 7$ *Ctrl* and 5 *iKO*). (B) Immunostaining of *Itpr2* and *APC* together with *Nkx2.2* and *Olig1* in the CC from P7 *control* (*Ctrl*) and *iKO* (*iKO*) mice. (Scale bars, 10 μm .) (C) Quantification of *Nkx2.2*⁺, *Itpr2*⁺, and *APC*⁺ cells (nb/mm²) in the CC of P7 *Ctrl* and *iKO* mice. Data are presented as mean \pm SEM ($n = 4$ *Ctrl* and 5 *iKO*). (D) Immunostaining of PDGFR α and *Nkx2.2* in the CC from P7 *Ctrl*, *iKO*, and *iKO*+PFT mice. (Scale bars, 10 μm .) (E) Quantification of *Nkx2.2*⁺ cells (nb/mm²) in the CC of P7 *Ctrl*, *iKO*, *Ctrl*+PFT and *iKO*+PFT mice. Data are presented as mean \pm SEM ($n = 3$ *Ctrl*, 5 *iKO*, 3 *Ctrl*+PFT and 3 *iKO*+PFT). (F) Summary representation of OL cell lineage progression in P7 *iKO* and *iKO*+PFT, mice. Circle size is proportional to the size of OL lineage cell-type population, as quantified in the CC. Dotted lines: OL population size in *Ctrl*. (G) Representative tracks for *Olig1*, *Olig2*, *Gpr17*, and *Mbp* locus integrating: (i) ChIP data for main oligodendroglial TFs (*Olig2* and *Sox10*) and chromatin remodeling factors (*Chd7*, *Chd8*) in OPCs and; (ii) ATAC data from *Ctrl* and *iKO* P7 OPCs. Exact *P* values can be found in Dataset S2. **P* < 0.05, ***P* < 0.01, and ****P* < 0.001.

OPCs, indicating that *Chd7* functions in OPC survival and differentiation can be dissociated (Fig. 6F).

To address *Chd7* remodeling function in the loci involved in OPC differentiation, we compared their chromatin accessibility in *Chd7iKO* OPCs and controls. Interestingly, OL differentiation genes bound by *Chd7*, such as *Olig2*, *Olig1*, and *Gpr17* (coding for a G protein-coupled receptor involved in OL differentiation), showed a decreased chromatin accessibility at regulatory regions in *Chd7* mutant OPCs compared with controls (Fig. 6G). Therefore, our findings indicate that *Chd7* promotes chromatin opening of key factors involved in OPC differentiation.

OPC Differentiation Requires both *Chd7* and *Chd8* Remodelers. To study whether *Chd8* and *Chd7* are required during OPC differentiation, we transfected neural progenitors derived from the neonatal SVZ of *Rosa26R^{lox-stop-YFP}* or *Chd7^{lox/+};Rosa26R^{lox-stop-YFP}* mice with lentivirus-expressing Cre-recombinase together with either *Chd8* shRNA or scramble shRNA (Fig. 7A). After 3 d in differentiation conditions favoring oligodendroglial differentiation (40% of cells) (*SI Appendix*, Fig. S12 A–C), *Chd7* and *Chd8* levels were found to be successfully reduced in *Chd8KD* (sh*Chd8*) and *Chd7cKO/+* (*Chd7^{lox/+}*) conditions compared with control (*ShScramble*), but the number of OPCs was not altered (*SI Appendix*, Fig. S12 D–H). At 6 d of differentiation, we found many iOLs expressing strong levels of both CNP and *Nkx2.2* (*SI Appendix*, Fig. S12I). Interestingly, while all genotypes showed comparable numbers of PDGFR α ⁺ OPCs and cell densities (Fig. 7 B and F), the ratio iOL/OPCs (*Nkx2.2*⁺/PDGFR α ⁺ cells) was reduced by 36% in *Chd8KD* cells (Fig. 7 B and C), suggesting a requirement of *Chd8* in OPC differentiation. Furthermore, while the loss of one *Chd7* allele (*Chd7cKO/+* cells) did not modify their OPC differentiation, its combination with *Chd8KD* further reduced iOL/OPC ratio (Fig. 7 B and C). These results thus indicate that *Chd7* and *Chd8* genetically interact in the process of OPC differentiation and suggest that *Chd8* may partially compensate the loss of *Chd7* during OPC differentiation.

***Chd7/Chd8* and *Olig2/Sox10* Bind to Regulatory Elements of Active Stage-Specific Genes in Oligodendroglia.** Finally, we further investigated the mechanisms by which *Chd7/Chd8* control gene expression in a timely manner during the course of OL cell lineage differentiation, integrating different datasets. An oligodendroglia single-cell transcriptome database (35) was used to classify genes according to their expression timing (Fig. 8A). Focusing on oligodendroglial stage-specific gene expression, we classified oligodendroglial-genes into three groups: (i) “OPC-genes” expressed in OPCs and down-regulated upon differentiation (e.g., *Ascl1*, *Cspg4*, *Pdgfra*); (ii) “iOL-genes” up-regulated and maintained upon early OPC differentiation (COPs of ref. 35; e.g., *Nkx2.2*, *Gpr17*, *Itpr2*); and (iii) “mOL-genes” up-regulated only in maturing OLs (NFOLs and mOLs; e.g., *Mbp*, *Mog*, *Omg*).

We then integrated the chromatin-binding profiles for key TFs (*Sox10* and *Olig2*), chromatin remodelers (*Chd7* and *Chd8*), and active histone marks (H3K4me3 and H3K27ac) (Fig. 8 and *SI Appendix*, Fig. S13) (present study and refs. 15 and 28) to analyze genes of each group (OPC-, iOL-, and mOL-genes; $n = 20$) (*SI Appendix*, Table S1). This integrative approach allowed us to identify four regulatory states, which are recapitulated in Fig. 8H and outlined as follows. State 1: Among not-yet-expressed genes, such as the majority of mOL-genes in OPCs, only a few are bound by *Chd7*, *Chd8*, and *Sox10*, while all are bound by *Olig2* in agreement with the pioneer factor function of *Olig2* (15). State 2: Among genes at their expression-onset (that start to be expressed), such as iOL-genes in OPCs, all are bound by *Chd8*, *Chd7*, and *Olig2* (to less extent by *Sox10*) at enhancers but only a few at their cognate promoters. State 3: Among robustly expressed genes, such as most OPC-genes in OPCs and iOL- and mOL-genes in OLs, all are bound by all factors (*Chd7*, *Chd8*,




Fig. 7. OPC differentiation requires both Chd7 and Chd8 remodelers. (A) Diagram representing transduction protocol used on neural stem cells (NSCs) with a lentivirus-expressing Cre and a scramble *shRNA* or a *shRNA* against *Chd8* and followed by fixation after 6 d of differentiation. (B) Immunostaining of Nkx2.2 and PDGFR α together with GFP in Ctrl (*ROSA26^{stop-floxed-YFP}* + scramble), *Chd8KD* (*ROSA26^{stop-floxed-YFP}* + *Chd8 shRNA*), *Chd7cKO/+* (*Chd7^{Flox1+}*; *ROSA26^{stop-floxed-YFP}* + scramble), or *Chd7cKO/+; Chd8KD* (*Chd7^{Flox1+}*; *ROSA26^{stop-floxed-YFP}* + *Chd8 shRNA*) conditions. White arrowheads represent PDGFR α ⁺-GFP⁺ OPCs and gray arrowheads represent Nkx2.2⁺-GFP⁺ iOLs. (Scale bars, 20 μ m.) (C and D) Ratio between Nkx2.2⁺-GFP⁺ iOLs and PDGFR α ⁺-GFP⁺ OPCs (C) and between Nkx2.2⁺-GFP⁺ iOLs and PDGFR α ⁺-GFP⁻ OPCs (D) in Ctrl, *Chd8KD*, *Chd7cKO/+*, and *Chd7cKO/+; Chd8KD* conditions. Data are presented as mean \pm SEM ($n = 4$). (E) Quantification of PDGFR α ⁺-GFP⁺ cells as a percentage of total GFP⁺ cells in Ctrl, *Chd8KD*, *Chd7cKO/+*, and *Chd7cKO/+; Chd8KD* conditions. Data are presented as mean \pm SEM ($n = 3$). (F) Quantification of cells (nb/mm²) in Ctrl, *Chd8KD*, *Chd7cKO/+*, and *Chd7cKO/+; Chd8KD* conditions. Data are presented as mean \pm SEM ($n = 3$). Exact *P* values can be found in Dataset S2. **P* < 0.05, ***P* < 0.01, and ****P* < 0.001.

Olig2, and Sox10) both at enhancers and their cognate promoters, suggesting that the presence of all these factors drive active gene transcription, with Sox10 preferentially binding active genes in OLs compared with OPCs. State 4: Among silenced genes (not expressed anymore), such as OPC-genes in OLs, all are still bound by Olig2 and Sox10, while a majority of them have lost Chd7 and Chd8 binding, suggesting that gene silencing is marked by, or results from, the lack of binding of chromatin remodelers, and not of TFs.

We therefore propose a dynamic model of cooperation between Chd7/Chd8 remodelers and Olig2/Sox10 key oligodendrogenic TFs to select and timely tune the gene-expression program at different OL lineage stages, in which the present of chromatin remodelers is key for robust gene transcription (SI Appendix, Fig. S14).

Discussion

Mounting evidence indicates that chromatin remodeling factors play important roles in normal development and neurodevelopmental diseases (46), with *CHD7* haploinsufficiency being the cause of CHARGE syndrome (47) and *CHD8* being one of the strongest ASD high-risk-associated genes (25). It is thus of relevance for human health to unravel the mechanisms controlled by Chd7/Chd8 chromatin remodelers and to understand how their haploinsufficiency leads to developmental brain pathology involved in these diseases. The present study addresses the mechanisms of gene-expression control by Chd7/Chd8 in OPCs, by generating and integrating genome-wide transcriptome, chromatin binding, and chromatin accessibility profiles of purified OPCs, isolated from control and OPC-specific *Chd7*-deficient mice. These experiences led to the following conclusions (SI Appendix, Fig. S15). First, Chd7 and Chd8 bind together to regulatory regions of genes involved in OPC differentiation, proliferation, and survival, suggesting that they regulate these different biological processes. Second, Chd7 protects OPCs from cell death through chromatin closing and direct transcriptional repression of the *p53/Trp53* promoter. Third, Chd7 is partially required to induce OPC differentiation through chromatin opening and transcriptional activation of key regulators of this process, although being dispensable for OL stage progression, consistent with Chd8 compensatory function, as suggested by Chd7/Chd8 common chromatin-binding profile and genetic synergy during OPC differentiation. Finally, integration of genome-wide occupancy repertoires and associated epigenetic signals from OL lineage cells suggests that Chd7/Chd8 remodelers and Olig2/Sox10 TFs cooperate to activate oligodendroglia stage-specific genes.

Chd7 Promotes OPC Survival Through Direct *p53/Trp53* Down-Regulation. Our timely controlled *Chd7* deletion in OPCs provided insights into *Chd7* function in proliferation and survival that were not directly addressed in our previous work using this time-controlled *Chd7* deletion (29). Interestingly, we found that *Chd7* OPC-specific deletion leads a selective apoptosis of noncycling OPCs and that the *p53/Trp53* transcripts were up-regulated in *Chd7*-deleted OPCs. Notably, *Trp53* heterozygosity has been recently shown to partially rescue the phenotypes of *Chd7*-null mouse embryos, and *p53* inappropriate activation leads to CHARGE syndrome traits (42). Here, we provide evidence that in vivo, Chd7 directly represses *p53/Trp53* expression in OPCs by binding and inducing chromatin closing at its promoter. These results are consistent with recent in vitro evidence for Chd7 binding to the *p53/Trp53* promoter in neural crest cells (42). Using a *p53* inhibitor (PFT), we were able to prevent *p53/Trp53* induction and cell death, thus restoring the pool of OPCs. It is worth noting that rescuing normal OPC numbers was not sufficient to restore normal OPC differentiation, indicating that Chd7 function in OPC survival can be dissociated from its role in promoting OPC differentiation.

The above results point out PFT as a potential treatment to reduce *p53* inappropriate expression in CHARGE patients. However, our PFT treatment rescued normal OPC numbers but not normal OPC differentiation, suggesting that targeting gene-networks promoting cell-differentiation may also be required to restore CHD7 function in CHARGE patients. The Chd7 direct repression of *p53/Trp53* in OPCs also has a potential interest in MS because MS brain tissues up-regulate *p53* expression (48), suggesting that a transient, and if possible brain-restricted, administration of




Fig. 8. Chd7/Chd8 and Olig2/Sox10 bind to regulatory elements of active stage-specific genes in oligodendroglia. (A) Diagram representing a set of genes with timely controlled expression (data from ref. 35) divided in three groups: OPC genes (*Ascl1* and *Pdgfra*), iOL genes (*Nkx2.2* and *Gpr17*), and mOL genes (*Mbp* and *Omg*). (B–G) Schematic representation from Genomatrix genome browser of *Ascl1* (B), *Pdgfra* (C), *Gpr17* (D), *Nkx2.2* (E), *Mbp* (F), and *Omg* (G) locus integrating ChIP-seq data for main oligodendroglial TFs (Olig2 and Sox10), chromatin remodeling factors (Chd7, Chd8), and active epigenetic marks (H3K27ac and H3K4me3) in OPCs and OLs. (H) Synthesis representation of the dynamic cooperation between TFs (Sox10, Olig2) and chromatin remodelers (Chd7, Chd8) for the timely regulation of OPC- and OL-gene expression with genes not yet expressed (1), genes starting to express (2), expressed genes (3), and genes not expressed anymore (4).

PFT to avoid possible proinflammatory effects (49), may help in the treatment of MS patients.

Diverse Chd7 Activities Regulate Different OPC Functions. Our ChIP-seq analyses on brain-purified OPCs allowed us to produce an in vivo genome-wide chromatin-binding profiling available for Chd7 and Chd8. In addition, the comparative transcriptome (RNA-seq) and chromatin accessibility (ATAC-seq) analyses performed between control and *Chd7*-deficient OPCs led us to demonstrate that Chd7 directly binds and opens chromatin at the enhancer and promoter regions of key regulators of OPC differentiation, such as *Sox10*, *Nkx2.2*, and *Gpr17*. The role of Chd7 in OPCs, as a chromatin-opening factor and activator of differentiation, is consistent with *Chd7* function in cerebellar granule progenitors (21). Remarkably, Chd7-binding properties differ between cell-types, as Chd7 binds to a completely different set of genes in OPCs and granule neuron progenitors and Chd7 also acts as a transcriptional repressor (closing chromatin) of many target genes in OPCs (e.g., *p53/Trp53*). These results raise important questions that remain to be elucidated: first, whether the cell-type-specific recruitment to regulatory elements of CHD remodelers depends on particular histone modifications and on the presence of cell-type-specific TFs; and second, what cofactors determine their chromatin-opening versus -closing activity.

Mechanisms of Time-Controlled Gene Expression During OPC Differentiation. We showed that in OL lineage cells, the binding of Chd7/8 to OL-lineage TF genes varies upon their lineage stage. This partial requirement of Chd7 during differentiation/maturation of *Chd7*-deficient OPCs result at least in part from a functional compensation provided by Chd8 which, like Chd7, binds to the majority of OL differentiation genes in OPCs. Together with our previous report on Chd7 expression during OL differentiation and myelination (28), and our complementary study on *Chd8* LOF

in OL lineage cells (37), the present results underscore CHD chromatin remodelers as key regulators of the progression along the differentiation/maturation pathway in OL lineage cells.

To further investigate the mechanisms regulating transcription during OL differentiation, herein we integrated oligodendroglia-specific chromatin profiling of chromatin remodelers (Chd7 and Chd8), key TFs (Sox10 and Olig2), and epigenetic histone marks (15, 28, 50). This integrative method highlighted a timely controlled binding of Chd7 and Chd8 to stage-specific genes in OPCs and OLs (Fig. 7). This finding leads us to propose a dynamic transcription regulatory model (*SI Appendix, Fig. S14*), including the following steps: (i) Olig2 pioneer TF (15, 51) binding to chromatin-enhancer elements; (ii) Olig2 binding-mediated recruitment of Chd7 and Chd8 on chromatin-enhancer elements; (iii) Chd7- and Chd8-induced chromatin opening, likely by sliding nucleosomes, results in Sox10 binding; (iv) additional clustering of other regulators together with DNA bending activity of the Sox10 HMG domain, allowing the mediator complex to form a stable promoter–enhancer loop; and (v) eventually, induction of robust transcription of OL differentiation genes. This timing of events could explain the crucial importance of Olig2 and Sox10 in activating OL lineage genes (12, 15), but also the partial compensation of Chd7 by Chd8 in OPC differentiation, cell survival, and likely proliferation. Remarkably, we found that in OLs, most of OPC-specific genes are still bound by Olig2 and Sox10 but not by Chd7/Chd8 remodelers (Fig. 7). This could imply that the loss of Chd7 and Chd8 binding, together with the recruitment of some repressors (e.g., *Nkx2.2*) (14), is required for down-regulation of OPC genes and subsequent OL differentiation.

Materials and Methods

Mice. Mice homozygous for *Chd7* floxed alleles (*Chd7^{Flox/Flox}*) (33) were crossed with *PDGFR α -CreER^T* (32) mice to generate the OPC-specific *Chd7*KO (*iKO*) mice. Animals of either sex were used in the study and *PDGFR α -CreER^T*

negative littermates were used as controls (*Ctrl*). All animal studies were conducted following protocols approved by Ethic Committee #5, Charles Darwin and French regulatory authorities (#03860.07).

Tamoxifen Administration. For conditional *Chd7* removal experiments, tamoxifen (T5648; Sigma) was dissolved in corn oil (C-8267; Sigma) and injected subcutaneously at 20-mg/mL concentration at postnatal stages P1 (40 μ L) and P4 (30 μ L) in *Ctrl* and *Chd7iKO* animals. Brains were then collected at P7.

PFT Administration. PFT (P4359; Sigma) was dissolved in DMSO (less than 10% final) and NaCl and injected subcutaneously at 0.8-mg/mL concentration at postnatal stages P3, P4, and P5 (5 μ L per day). Brains were collected at P7.

OPC MACSorting. Dissociation of cortex and CC from *Ctrl*, *Chd7iKO*, or wild-type P7 mice was done using neural tissue dissociation kit (P) (130-093-231; Miltenyi Biotec) and dissociator (130-096-427). Magnetic sorting was done using anti-O4-coupled-beads (130-094-543) and the MultiMACS Cell24 Separator Plus (130-098-637). O4⁺ cells were collected in PBS before being processed to RNA-seq, ATAC-seq or CHIP-seq.

- Fünfschilling U, et al. (2012) Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. *Nature* 485:517–521.
- Lee Y, et al. (2012) Oligodendroglia metabolically support axons and contribute to neurodegeneration. *Nature* 487:443–448.
- Mount CW, Monje M (2017) Wrapped to adapt: Experience-dependent myelination. *Neuron* 95:743–756.
- Spassky N, et al. (1998) Multiple restricted origin of oligodendrocytes. *J Neurosci* 18:8331–8343.
- Tekki-Kessariss N, et al. (2001) Hedgehog-dependent oligodendrocyte lineage specification in the telencephalon. *Development* 128:2545–2554.
- Rowitch DH (2004) Glial specification in the vertebrate neural tube. *Nat Rev Neurosci* 5:409–419.
- Ffrench-Constant C, Raff MC (1986) The oligodendrocyte-type-2 astrocyte cell lineage is specialized for myelination. *Nature* 323:335–338.
- Suzuki SO, Goldman JE (2003) Multiple cell populations in the early postnatal subventricular zone take distinct migratory pathways: A dynamic study of glial and neuronal progenitor migration. *J Neurosci* 23:4240–4250.
- Bergles DE, Richardson WD (2015) Oligodendrocyte development and plasticity. *Cold Spring Harb Perspect Biol* 8:a020453.
- Emery B, Lu QR (2015) Transcriptional and epigenetic regulation of oligodendrocyte development and myelination in the central nervous system. *Cold Spring Harb Perspect Biol* 7:a020461.
- Küspert M, Wegner M (2016) Something 2 talk about—Transcriptional regulation in embryonic and adult oligodendrocyte precursors. *Brain Res* 1638:167–182.
- Stolt CC, et al. (2002) Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor Sox10. *Genes Dev* 16:165–170.
- Nakatani H, et al. (2013) *Ascl1/Mash1* promotes brain oligodendrogenesis during myelination and remyelination. *J Neurosci* 33:9752–9768.
- Qi Y, et al. (2001) Control of oligodendrocyte differentiation by the *Nkx2.2* homeodomain transcription factor. *Development* 128:2723–2733.
- Yu Y, et al. (2013) *Olig2* targets chromatin remodelers to enhancers to initiate oligodendrocyte differentiation. *Cell* 152:248–261.
- Zaret KS, Mango SE (2016) Pioneer transcription factors, chromatin dynamics, and cell fate control. *Curr Opin Genet Dev* 37:76–81.
- Schnetz MP, et al. (2010) *CHD7* targets active gene enhancer elements to modulate ES cell-specific gene expression. *PLoS Genet* 6:e1001023.
- Schulz Y, et al. (2014) *CHD7*, the gene mutated in CHARGE syndrome, regulates genes involved in neural crest cell guidance. *Hum Genet* 133:997–1009.
- Feng W, et al. (2013) The chromatin remodeler *CHD7* regulates adult neurogenesis via activation of *Sox2* transcription factors. *Cell Stem Cell* 13:62–72.
- Micucci JA, et al. (2014) *CHD7* and retinoic acid signaling cooperate to regulate neural stem cell and inner ear development in mouse models of CHARGE syndrome. *Hum Mol Genet* 23:434–448.
- Feng W, et al. (2017) *Chd7* is indispensable for mammalian brain development through activation of a neuronal differentiation programme. *Nat Commun* 8:14758.
- Cotney J, et al. (2015) The autism-associated chromatin modifier *CHD8* regulates other autism risk genes during human neurodevelopment. *Nat Commun* 6:6404.
- Katayama Y, et al. (2016) *CHD8* haploinsufficiency results in autistic-like phenotypes in mice. *Nature* 537:675–679.
- Jongmans MC, et al. (2009) *CHD7* mutations in patients initially diagnosed with Kallmann syndrome—The clinical overlap with CHARGE syndrome. *Clin Genet* 75:65–71.
- Bernier R, et al. (2014) Disruptive *CHD8* mutations define a subtype of autism early in development. *Cell* 158:263–276.
- O’Roak BJ, et al. (2012) Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature* 485:246–250.
- Hartshorne TS, Grialou TL, Parker KR (2005) Autistic-like behavior in CHARGE syndrome. *Am J Med Genet A* 133A:257–261.
- He D, et al. (2016) *Chd7* cooperates with *Sox10* and regulates the onset of CNS myelination and remyelination. *Nat Neurosci* 19:678–689.
- Batsukh T, et al. (2012) Identification and characterization of *FAM124B* as a novel component of a *CHD7* and *CHD8* containing complex. *PLoS One* 7:e26240.
- Schnetz MP, et al. (2009) Genomic distribution of *CHD7* on chromatin tracks *H3K4* methylation patterns. *Genome Res* 19:590–601.
- Creyghton MP, et al. (2010) Histone *H3K27ac* separates active from poised enhancers and predicts developmental state. *Proc Natl Acad Sci USA* 107:21931–21936.
- Kang SH, Fukaya M, Yang JK, Rothstein JD, Bergles DE (2010) *NG2*⁺ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. *Neuron* 68:668–681.
- Hurd EA, Poucher HK, Cheng K, Raphael Y, Martin DM (2010) The ATP-dependent chromatin remodeling enzyme *CHD7* regulates pro-neural gene expression and neurogenesis in the inner ear. *Development* 137:3139–3150.
- Zhang Y, et al. (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J Neurosci* 34:11929–11947.
- Marques S, et al. (2016) Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. *Science* 352:1326–1329.
- Sugathan A, et al. (2014) *CHD8* regulates neurodevelopmental pathways associated with autism spectrum disorder in neural progenitors. *Proc Natl Acad Sci USA* 111:E4468–E4477.
- Zhao C, et al. (2018) Dual requirement of *CHD8* for chromatin landscape establishment and histone methyltransferase recruitment to promote CNS myelination and repair. *Dev Cell* 45:753–768.e758.
- Subtil-Rodriguez A, et al. (2013) The chromatin remodeler *CHD8* is required for E2F-dependent transcription activation of S-phase genes. *Nucleic Acids Res* 42:2185–2196.
- Stergachis AB, et al. (2014) Conservation of trans-acting circuitry during mammalian regulatory evolution. *Nature* 515:365–370.
- Willsey AJ, et al. (2013) Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. *Cell* 155:997–1007.
- Liu L, et al. (2014) DAWN: A framework to identify autism genes and subnetworks using gene expression and genetics. *Mol Autism* 5:22.
- Van Nostrand JL, et al. (2014) Inappropriate p53 activation during development induces features of CHARGE syndrome. *Nature* 514:228–232.
- Buenostro JD, Wu B, Chang HY, Greenleaf WJ (2001) ATAC-seq: A method for assaying chromatin accessibility genome-wide. *Curr Protoc Mol Biol* 109:21.29.1–21.29.9.
- Murphy PJM, et al. (2004) *Pif1* inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. *J Biol Chem* 279:30195–30201.
- Lang J, et al. (2013) Adenomatous polyposis coli regulates oligodendroglial development. *J Neurosci* 33:3113–3130.
- Yoo AS, Crabtree GR (2009) ATP-dependent chromatin remodeling in neural development. *Curr Opin Neurobiol* 19:120–126.
- Visser LE, et al. (2004) Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. *Nat Genet* 36:955–957.
- Li J, et al. (2008) Inhibition of p53 transcriptional activity: A potential target for future development of therapeutic strategies for primary demyelination. *J Neurosci* 28:6118–6127.
- Gudkov AV, Gurova KV, Komarova EA (2011) Inflammation and p53: A tale of two stresses. *Genes Cancer* 2:503–516.
- He D, et al. (2017) lncRNA functional networks in oligodendrocytes reveal stage-specific myelination control by an lncOL1/Suz12 complex in the CNS. *Neuron* 93:362–378.
- Raposo AA, et al. (2015) *Ascl1* coordinately regulates gene expression and the chromatin landscape during neurogenesis. *Cell Rep* 10:1544–1556.